Core Viewpoint - The supervisory board of Shenzhen BGI Tech Co., Ltd. has approved several key proposals during its 15th meeting, including the 2025 semi-annual report and various incentive plans aimed at enhancing the company's market competitiveness and operational efficiency [1][2][3][4][5][6][7] Group 1: Semi-Annual Report - The supervisory board approved the 2025 semi-annual report, confirming that it complies with relevant laws and accurately reflects the company's financial and operational status [1][2] - The voting outcome for this proposal was unanimous, with 3 votes in favor and no opposition or abstentions [2] Group 2: Fund Management - The board also approved a special report on the management of raised funds for the first half of 2025, affirming that the funds were stored and used in accordance with regulatory requirements [2] - This proposal also received unanimous approval with 3 votes in favor [2] Group 3: Stock Incentive Plans - The board reviewed and approved revisions to the 2024 Restricted Stock Incentive Plan to better align with the company's strategic goals and enhance market competitiveness [3][4] - The revisions to the incentive plan are in compliance with relevant regulations and do not harm the interests of the company or its shareholders [3][4] - The voting outcome for this proposal was unanimous, with 3 votes in favor [4] Group 4: Employee Stock Ownership Plan - The board approved revisions to the 2024 Employee Stock Ownership Plan, aimed at incentivizing the core team to increase market share among non-related clients [5][6] - Due to conflicts of interest, the voting on this proposal will be submitted to the shareholders' meeting for approval, as the number of non-related supervisors present was insufficient for a valid decision [6][7] - The board also approved revisions to the management measures of the employee stock ownership plan to ensure consistency and rationality in the incentive assessment system [6][7]

Meeting Overview - The shareholder meeting is scheduled for September 8, 2025, at 15:00 [1] - The meeting will be held at the International Conference Center, Huada Space Center, Shenzhen [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's voting system [1] Voting Procedures - The online voting period is from September 8, 2025, with specific time slots for trading system voting [1] - Shareholders must complete identity verification to vote online for the first time [4] - Duplicate voting through different methods will be resolved by considering the first vote cast [4] Agenda Items - The meeting will review several proposals related to the 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan [2][3] - Specific proposals include the draft and management methods for the incentive plans, which have been approved by the board and supervisory committee [2] Attendance Requirements - Shareholders registered by the close of trading on September 3, 2025, are eligible to attend [4] - Proxy representation is allowed, and specific documentation is required for attendance [5] Registration Details - Registration for the meeting is set for September 5, 2025, with specified times and location for registration [5] - Required documents include valid identification and proof of shareholding [5] Additional Information - Attendees are responsible for their own travel and accommodation expenses [5] - Contact information for inquiries is provided, including email and phone numbers [5]

Core Viewpoint - Shenzhen Huada Zhi Zao Technology Co., Ltd. is revising its 2024 employee stock ownership plan to enhance employee motivation and align with the company's strategic direction [5][11]. Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the revision of the employee stock ownership plan, complying with relevant regulations [5][11]. - The plan's related proposals have been submitted for review at the company's shareholders' meeting [11]. Group 2: Reasons and Main Content of the Revision - The revision aims to adjust the company's performance assessment targets to stimulate employee engagement and support sustainable business development [8][11]. - The main content of the revision includes changes to the performance assessment requirements, with specific targets set for the years 2024 and 2025 based on the company's revenue from 2023, which was 2.709 billion [8][9]. Group 3: Performance Assessment Targets - The performance assessment for the employee stock ownership plan will be based on revenue growth rates, with specific targets set for each assessment period [9][10]. - The first unlock period for 2024 has a trigger value of 15% and a target value of 20%, while the second unlock period for 2025 has a trigger value of 32% and a target value of 44% [8][9].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. has proposed a 2024 employee stock ownership plan aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][10][21]. Summary by Sections 1. Purpose and Principles of the Plan - The employee stock ownership plan is designed to establish a profit-sharing mechanism between employees and shareholders, improve corporate governance, and enhance employee motivation and creativity [10][11]. - Participation in the plan is voluntary, and the company will not impose mandatory participation on employees [11][12]. 2. Participants and Eligibility - The plan will include a maximum of 35 employees, consisting of directors (excluding independent directors), supervisors, senior management, and core business personnel [4][12]. - The selection of participants will be based on their contributions to the company's core business and strategic direction [15]. 3. Funding and Stock Source - The total funding for the plan will not exceed RMB 37.7868 million, with each unit priced at RMB 1.00 [4][13]. - The shares will be sourced from the company's repurchased A-shares, with a maximum holding of 1.445 million shares, accounting for 0.35% of the total share capital [5][18]. 4. Pricing and Valuation - The share purchase price is set at RMB 26.15 per share, which is based on the average trading price prior to the announcement of the plan [15][16]. - The pricing strategy aims to ensure fairness and reasonableness, reflecting the company's operational status and industry conditions [16]. 5. Lock-up and Vesting Period - The plan has a duration of 48 months, with shares vesting in two phases: 50% after 12 months and the remaining 50% after 24 months [6][20]. - The vesting of shares is contingent upon the company's performance and individual assessments of the participants [20][21]. 6. Management and Governance - The plan will be managed by a dedicated management committee, which will oversee daily operations and represent the interests of the participants [24][25]. - The management committee is responsible for ensuring compliance with legal and regulatory requirements and safeguarding the rights of the participants [25][29]. 7. Performance Assessment - The performance assessment will be based on company-wide revenue growth and individual performance metrics, with specific targets set for the years 2024 and 2025 [21][22]. - The assessment results will determine the unlock ratios for the shares, aligning employee incentives with company performance [22][23].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has proposed a 2024 Employee Stock Ownership Plan (ESOP) aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][12][16]. Group 1: Plan Overview - The ESOP is designed to comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3][12]. - The plan will be managed by a dedicated committee, which will represent the interests of the participants and ensure compliance with legal requirements [9][25]. - The total amount to be raised through the plan is capped at RMB 37.7868 million, with each unit priced at RMB 1.00 [4][14]. Group 2: Participants and Structure - The plan will involve a maximum of 35 employees, including directors (excluding independent directors), supervisors, senior management, and core business personnel [4][13]. - The stock purchase price is set at RMB 26.15 per share, which is based on a fair valuation considering the company's performance and market conditions [15][16]. - The total shares allocated under the plan will not exceed 1.445 million shares, representing approximately 0.35% of the company's total share capital [5][18]. Group 3: Lock-up and Vesting - The plan has a duration of 48 months, with shares unlocking in two phases: 50% after 12 months and the remaining 50% after 24 months [6][21]. - The unlocking of shares is contingent upon the company's performance meeting specific revenue growth targets, which are set against the 2023 revenue of RMB 2.709 billion [22][23]. Group 4: Financial Management and Compliance - The company will not provide any financial assistance to participants, ensuring that all funding comes from employees' legal salaries and self-raised funds [4][14]. - The management committee will oversee the daily operations of the ESOP, ensuring that all actions comply with the established guidelines and protect the rights of the participants [25][30]. - The plan includes provisions for adjusting the stock purchase price in the event of corporate actions such as stock splits or dividends [16][17].

Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement Return Action Plan" for 2025, focusing on optimizing operations and enhancing returns to investors while navigating market challenges and opportunities [1]. Group 1: Business Performance and Strategy - The company has centered its operations around gene sequencing, leading to sustained growth across three major business lines despite competitive pressures and price declines in the industry [2][3]. - The company achieved a historical high in sales of its all-read long sequencing business (SEQ ALL), with over 700 units sold, marking a year-on-year growth of 60.35% [2]. - The company has expanded its global footprint, with cumulative sales of gene sequencing instruments exceeding 5,300 units, indicating a significant milestone [2]. Group 2: Market Expansion and Development - The company is actively pursuing a global strategy, focusing on diversifying its market presence in regions like Europe, Africa, and the Middle East to mitigate risks associated with single-market dependency [1][3]. - In the Asia-Pacific region, the company has successfully delivered 50,000 samples for the Thailand Genome Project and is advancing projects in Indonesia and South Australia [4]. - The company has established new customer relationships in various regions, including 22 new clients in the Asia-Pacific and 28 in the Americas, enhancing its market penetration [5][6]. Group 3: Product Development and Innovation - The company is advancing its product lines by integrating short-read and long-read sequencing technologies, aiming for automation and intelligent solutions in laboratory processes [9][10]. - The company has achieved significant growth in its multi-omics business, with revenue increasing by over 40% year-on-year, driven by product upgrades and market expansion [3][10]. - The company has obtained numerous certifications for its high-throughput sequencing products, enhancing its competitive edge in global markets [10]. Group 4: Financial Management and Efficiency - The company has invested approximately 1.574 billion RMB in its initial public offering projects, focusing on the development of semiconductor-based sequencing instruments and marketing service centers [8]. - The company is enhancing its financial management by improving accounts receivable turnover and optimizing credit management to accelerate cash flow [8][9]. - The company is implementing budget management strategies to align expenses with revenue forecasts, thereby improving operational efficiency [9]. Group 5: Governance and Compliance - The company has established a market value management system to enhance compliance and protect the rights of investors and stakeholders [11]. - The company has improved its ESG ratings, achieving an AA rating from Wind ESG, reflecting its commitment to sustainable development and enhancing investor confidence [11]. - The company is actively engaging with investors through various communication channels, including online and offline meetings, to foster transparency and trust [12].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. reported on the management and usage of raised funds for the first half of 2025, detailing the total amount raised, its allocation, and the current balance of funds [1][3]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was approximately RMB 3.60 billion, with a net amount of RMB 3.31 billion after deducting issuance costs [1][3]. - As of December 31, 2024, the balance of the raised funds was RMB 1.82 billion, which decreased to RMB 1.67 billion by June 30, 2025, after accounting for usage and interest income [1][2]. Fund Usage and Management - The company has established a fundraising management system to ensure proper storage and usage of the funds, adhering to relevant regulations [1][3]. - The company signed tripartite and quadripartite agreements with its sponsor and banks to regulate the management of the raised funds [1][3]. Fund Allocation - The actual usage of the raised funds for the reporting period was RMB 39.11 million, with a cumulative total of RMB 1.57 billion used to date [3][4]. - There were no instances of using idle funds for temporary working capital or for repaying bank loans during the reporting period [3][4]. Project Status and Adjustments - The company completed the investment projects "BGI Intelligent Manufacturing Information System Construction" and "BGI Intelligent Manufacturing Marketing Service Center Construction," leading to a decision to permanently supplement working capital with the remaining funds [3][4]. - The timeline for the "BGI Intelligent Manufacturing and R&D Base Project" has been extended to March 2026 due to construction delays [3][4]. Financial Management - The company has engaged in cash management for idle funds, investing in high-security and liquid financial products, with a total of RMB 868 million allocated to various structured deposits [2][4]. - The company reported an investment income of RMB 16.28 million from these financial products, which has been returned to the fundraising account [4][6].

Core Points - Shenzhen BGI Tech Co., Ltd. held the first meeting of the 2024 Employee Stock Ownership Plan on August 21, 2025, with 25 attendees representing 34,797,962 shares, accounting for 94.40% of the total shares in the plan [1][2] - The meeting approved the revised draft of the 2024 Employee Stock Ownership Plan and its summary to ensure the smooth implementation of the plan and protect the rights of shareholders [1] - The meeting also approved the revised management measures for the 2024 Employee Stock Ownership Plan, aligning with relevant regulations and actual circumstances [2] Summary by Sections Employee Stock Ownership Plan - The 2024 Employee Stock Ownership Plan was discussed and approved, with a focus on performance assessment indicators at the company level to ensure its effectiveness [1] - The plan's total shares represented by attendees was 34,797,962, with unanimous approval (100%) from those present [2] Management Measures - The management measures for the 2024 Employee Stock Ownership Plan were revised to align with the updated draft and ensure smooth implementation [2] - The voting results showed full support with no opposition or abstentions [2]

Core Viewpoint - The legal opinion letter issued by Junhe Law Firm confirms that Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. has obtained the necessary approvals and authorizations for the revision of its 2024 restricted stock incentive plan, which aims to enhance the motivation of incentive targets and align with the company's strategic direction [4][12]. Group 1: Approval and Authorization - The company has completed the necessary procedures for the revision of the incentive plan, including resolutions from the board of directors and supervisory board [4][9]. - The independent directors have publicly solicited proxy voting rights from shareholders regarding the relevant proposals for the incentive plan [5][6]. - The supervisory board has verified the list of incentive targets and issued relevant opinions [6][8]. Group 2: Reasons and Main Content of the Revision - The revision aims to adjust the performance assessment targets at the company level to stimulate the enthusiasm of incentive targets and promote sustainable business development [9][12]. - The main content of the revision includes adjustments to the performance assessment requirements in the incentive plan, with the assessment period set for the 2024-2025 fiscal years [9][11]. - The performance assessment will be based on the company's 2023 revenue of 2.709 billion yuan, excluding revenue related to public health emergencies, with specific growth targets set for each assessment year [10][11]. Group 3: Performance Assessment Targets - The performance assessment targets for the first and second vesting periods are set at 20% and 44% growth, respectively, based on the 2023 revenue [9][10]. - The assessment will also consider the sales growth of gene sequencers, with specific targets established for each year [11][12]. - Adjustments to the performance targets may occur in the event of significant corporate changes affecting revenue [10][12].

Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].